Pharmaceutical company Eli Lilly announced promising clinical trial results for a daily pill to treat obesity and diabetes, a considerable advantage over other GLP-1-based weight-loss drugs that have ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

While pharmaceuticals have so far been spared from import taxes, Trump has vowed to impose a “major” tariff on the sector ...